Compare DLHC & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | VRCA |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.8M | 87.5M |
| IPO Year | 2012 | 2018 |
| Metric | DLHC | VRCA |
|---|---|---|
| Price | $5.71 | $6.47 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 6.4K | ★ 75.6K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,923,000.00 | $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.05 | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.57 | ★ 370.22 |
| 52 Week Low | $3.41 | $0.39 |
| 52 Week High | $8.09 | $9.82 |
| Indicator | DLHC | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 61.74 |
| Support Level | $5.55 | $5.16 |
| Resistance Level | $6.05 | $8.08 |
| Average True Range (ATR) | 0.26 | 0.43 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 49.58 | 84.16 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.